Breathtaking science
Developing innovative therapeutics to transform
the standard of care for respiratory diseases
25 June 2019
Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine
LONDON, June 25, 2019 (GLOBE NEWSWIRE) -- Verona Pha…
4 June 2019
Watch our latest videos about living with COPD, the significant unmet need and ensifentrine
Our lead product, ensifentrine (RPL554), is first-in-class. It offers a unique, dual mechanism of action unlike any other type of drug currently available or in development for respiratory diseases
54.00p
0.00 (0.00%)
LON: VRP
4.93USD
-0.17 (-3.28%)
NASDAQ: VRNA
Verona Pharma plc
3 More London Riverside
London SE1 2RE
United Kingdom
E: info@veronapharma.com
T: +44 (0)203 283 4200
Registered address
One Central Square
Cardiff CF10 1FS
United Kingdom
US Investor relations contact
Westwicke, an ICR Company
E: ICR_Verona@icrinc.com
T: +1 203 919 7905
European Investor relations contact
Optimum Strategic Communications
E:verona@optimumcomms.com
T:+44 (0)203 922 0891
Nominated adviser and broker
Nplus1 Singer Advisory LLP
One Bartholomew Lane
London EC2N 2AX
United Kingdom
T: +44 (0)203 283 4200